Abstract | PURPOSE: METHODS AND MATERIALS: Mice received either single-dose (10, 15, 20, or 25 Gy) or fractioned irradiation (cumulative dose up to 30 Gy) of the head-and-neck area with or without subcutaneous injection of pharmacologically optimized flagellin, CBLB502, 30 min before irradiation. RESULTS:
CBLB502 significantly reduced the severity of dermatitis and mucositis, accelerated tissue recovery, and reduced the extent of radiation induced weight loss in mice after a single dose of 15 or 20 Gy but not 25 Gy of radiation. CBLB502 was also protective from cumulative doses of 25 and 30 Gy delivered in two (10 + 15 Gy) or three (3 × 10 Gy) fractions, respectively. While providing protection to normal epithelia, CBLB502 did not affect the radiosensitivity of syngeneic squamous carcinoma SCCVII grown orthotopically in mice. Use of CBLB502 also elicited a radiation independent growth inhibitory effect upon TLR5-expressing tumors demonstrated in the mouse xenograft model of human lung adenocarcinoma A549. CONCLUSION:
|
Authors | Lyudmila G Burdelya, Anatoli S Gleiberman, Ilia Toshkov, Semra Aygun-Sunar, Meghana Bapardekar, Patricia Manderscheid-Kern, David Bellnier, Vadim I Krivokrysenko, Elena Feinstein, Andrei V Gudkov |
Journal | International journal of radiation oncology, biology, physics
(Int J Radiat Oncol Biol Phys)
Vol. 83
Issue 1
Pg. 228-34
(May 01 2012)
ISSN: 1879-355X [Electronic] United States |
PMID | 22000579
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2012 Elsevier Inc. All rights reserved. |
Chemical References |
- CBLB502
- Peptides
- Radiation-Protective Agents
- Toll-Like Receptor 5
|
Topics |
- Adenocarcinoma
(metabolism)
- Animals
- Carcinoma, Squamous Cell
(radiotherapy)
- Cell Line, Tumor
- Female
- Head and Neck Neoplasms
(radiotherapy)
- Humans
- Lung Neoplasms
(metabolism)
- Mice
- Mouth Mucosa
(radiation effects)
- Peptides
(therapeutic use)
- Radiation Injuries, Experimental
(prevention & control)
- Radiation Tolerance
(drug effects)
- Radiation-Protective Agents
(therapeutic use)
- Radiodermatitis
(prevention & control)
- Stomatitis
(etiology, prevention & control)
- Toll-Like Receptor 5
(agonists, metabolism)
- Weight Loss
(drug effects)
- Xenograft Model Antitumor Assays
(methods)
|